Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Toxicology Drug Screening Market Growth From $23.49 Billion In 2026 To $33.47 Billion By 2030 At A CAGR Of 9.2%
The toxicology drug screening market size has seen robust growth in recent years. It is forecast to expand from $21.44 billion in 2025 to $23.5 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.6%. The expansion observed historically can be attributed to the reliance on manual toxicology testing methods, limited laboratory automation, the increasing prevalence of substance abuse monitoring, tightening regulatory oversight, and the adoption of conventional bioanalytical instrumentation.
The toxicology drug screening market is anticipated to show significant expansion in the upcoming years. Its value is projected to reach $33.48 billion by 2030, growing at a compound annual growth rate (CAGR) of 9.2%. This expected increase during the forecast period can be attributed to the advancement of AI-driven predictive toxicology tools, the integration of genomics and transcriptomics into screening, the rise of contract research organizations (CROs), an escalating demand for real-time drug monitoring systems, and the implementation of cloud-based and secure data management platforms. Notable trends for this period include the increasing adoption of high-throughput screening technologies, the integration of LIMS and laboratory information systems, the growing utilization of predictive and AI-powered toxicology platforms, the expansion of workplace drug screening programs, and a strengthened focus on data security and compliance standards.
Get A Free Sample Report With In-Depth Market Insights:
Toxicology Drug Screening Market Development Factors: What’s Supporting Demand?
The escalating incidence of drug abuse is anticipated to drive the growth of the toxicology drug screening market moving forward. Drug abuse refers to the damaging or excessive consumption of drugs for non-medical intentions, which negatively impacts a person’s health and daily life. The rise in drug abuse prevalence is attributed to increased stress and mental health struggles, leading many individuals to improperly use substances as a coping strategy. Toxicology drug screening is valuable in the context of drug abuse because it aids in identifying the presence of drugs or their metabolites within an individual’s body, thus enabling timely recognition, diagnosis, and management of substance misuse or overdose situations. For instance, in August 2024, information from the National Records of Scotland (NRS), a Scotland-based government department, showed that Scotland recorded 1,172 drug misuse deaths in 2023, representing a 12% rise (121 additional deaths) compared to 2022. Hence, the increasing prevalence of drug abuse is a primary stimulant for the toxicology drug screening market.
Toxicology Drug Screening Market Segment Breakdown: Which Categories Lead On Revenue?
The toxicology drug screening market covered in this report is segmented –
1) By Type: Screening Assays, Analytical Confirmatory Tests, Sample Collection Devices, Laboratory Consumables, Rapid Point-of-Care Tests, Laboratory Software And Reporting Systems
2) By Test Type: Acute Systemic Toxicity, Dermal Toxicity, Carcinogenicity, Ocular Toxicity, Genotoxicity, Neurotoxicity, Organ-Specific Toxicity
3) By Technology Type: High-Throughput Screening, Genomics, Transcriptomics, Toxicogenomics, Molecular Screening
4) By Application: Immunotoxicity, Systemictoxicity, Developmental And Reproductive Toxicity (DART), Endocrine Disruption, Other Applications
5) By End Users: Hospitals, Clinics, Contract Research Organizations (CROs), Pharmaceutical Companies, Workplace Testing Facilities
Subsegments:
1) By Screening Assays: Immunoassay Drug Screening Kits, Enzyme-Linked Immunosorbent Assay (ELISA) Kits, Lateral Flow Rapid Screening Assays, Fluorescence Polarization Immunoassays
2) By Analytical Confirmatory Tests: Gas Chromatography–Mass Spectrometry (GC-MS), Liquid Chromatography–Mass Spectrometry (LC-MS/MS), High-Performance Liquid Chromatography (HPLC), Capillary Electrophoresis Toxicology Tests
3) By Sample Collection Devices: Urine Drug Collection Cups, Saliva (Oral Fluid) Collection Devices, Blood Collection Tubes, Hair Drug Collection Kits
4) By Laboratory Consumables: Calibrators And Controls, Reagents And Buffers, Extraction Cartridges And Columns, Sample Preparation Kits
5) By Rapid Point-of-Care Tests: Multi-Panel Urine Dip Cards, Saliva Drug Screening Cassettes, Breath Alcohol And Drug Screening Devices, Single-Drug Detection Test Strips
6) By Laboratory Software And Reporting Systems: Laboratory Information Management Systems (LIMS), Toxicology Reporting And Result Interpretation Software, Chain-of-Custody Tracking Software, Compliance And Audit Documentation Systems
Toxicology Drug Screening Market Transformation Trends: What Innovations Are Driving Change?
Major companies within the toxicology drug screening market are focusing on implementing innovative solutions, such as the 3D liver microphysiological system, which facilitates the culturing of highly biomimetic human liver microtissues featuring organized cellular structures and active metabolic function. The 3D liver microphysiological system (MPS) serves as an advanced in vitro platform, specifically engineered to more accurately replicate the human liver’s physiological microenvironment than traditional cell culture methods, and typically involves growing multiple types of human liver cells. For example, in February 2025, CN Bio Innovations Ltd., a U.K.-based life sciences company specializing in organ-on-a-chip (OOC) technologies, launched the PhysioMimix DILI assay kit. This all-in-one laboratory kit is developed for the in vitro profiling of human drug-induced liver injury and includes a highly characterized 3D liver microphysiological system (MPS) that successfully recreates metabolically active, highly functional human liver tissue and Kupffer cells. Additionally, it offers simple integration of organ-on-a-chip technology with a plug-and-play format, thereby simplifying deployment and reducing time to adoption.
Toxicology Drug Screening Market Leading Players And Competitive Positioning
Major companies operating in the toxicology drug screening market are Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Merck KGaA, Siemens Healthineers, BD Bioscience, Quest Diagnostics, ICON plc, Agilent Technologies Inc., Eurofins Scientific SE, Wuxi AppTec, Charles River Laboratories International Inc., Shimadzu Corporation, Waters Corporation, Bio-Rad Laboratories Inc., Bruker Corporation, Evotec AG, Promega Corporation, The Jackson Laboratory, Clinical Reference Laboratory Inc., Enzo Life Sciences Inc., Covance Inc., Randox Toxicology, Alere Inc.
View The Full Toxicology Drug Screening Market Report:
Toxicology Drug Screening Market Top Region By Revenue And Market Share
North America was the largest region in the toxicology drug screening market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the toxicology drug screening market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model








